Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mourad Wahba

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Therapeutic Advances in Psychopharmacology|April 28, 2022
Will psilocybin lose its magic in the clinical setting?Caroline Hayes, Mourad Wahba, Stuart Watson
Bjpsych Open|December 10, 2024
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experienceMourad Wahba, Caroline Hayes, Maartje Kletter, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 10, 2019
Authors' replyMourad Wahba, Soraia Sousa, Stuart Watson, et al.
Journal of Affective Disorders|March 25, 2026
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
BMJ Open|March 19, 2026
Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocolLumbini Azim, Sarah Al-Ashmori, Chrissie Butcher, et al.
Journal of Affective Disorders|December 20, 2024
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|October 11, 2025
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
The Lancet. Psychiatry|July 2, 2025
Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UKMichael Browning, Philip J Cowen, Ushma Galal, et al.
Journal of Affective Disorders|February 5, 2023
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
The New England Journal of Medicine|November 2, 2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major DepressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Therapeutic Advances in Psychopharmacology|April 28, 2022
Will psilocybin lose its magic in the clinical setting?Caroline Hayes, Mourad Wahba, Stuart Watson
Bjpsych Open|December 10, 2024
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experienceMourad Wahba, Caroline Hayes, Maartje Kletter, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 10, 2019
Authors' replyMourad Wahba, Soraia Sousa, Stuart Watson, et al.
Journal of Affective Disorders|March 25, 2026
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
BMJ Open|March 19, 2026
Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocolLumbini Azim, Sarah Al-Ashmori, Chrissie Butcher, et al.
Journal of Affective Disorders|December 20, 2024
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders|October 11, 2025
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
The Lancet. Psychiatry|July 2, 2025
Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UKMichael Browning, Philip J Cowen, Ushma Galal, et al.
Journal of Affective Disorders|February 5, 2023
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
The New England Journal of Medicine|November 2, 2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major DepressionGuy M Goodwin, Scott T Aaronson, Oscar Alvarez, et al.
Pageof 1